- Report
- July 2023
- 141 Pages
Asia Pacific
From €1362EUR$1,500USD£1,173GBP
- Report
- July 2023
- 141 Pages
Europe
From €1362EUR$1,500USD£1,173GBP
- Report
- July 2023
- 128 Pages
North America
From €1362EUR$1,500USD£1,173GBP
- Report
- July 2023
- 141 Pages
Middle East, Africa
From €1362EUR$1,500USD£1,173GBP
- Report
- October 2024
- 81 Pages
Global
From €3500EUR$4,130USD£3,121GBP
- Report
- May 2023
- 79 Pages
Global
From €3500EUR$4,130USD£3,121GBP
- Report
- November 2025
- 132 Pages
Global
From €862EUR$950USD£743GBP
The Thrombosis Drug market is a subset of the Cardiovascular Drugs market, which focuses on the prevention and treatment of blood clots. Thrombosis drugs are used to reduce the risk of stroke, heart attack, and other cardiovascular events. These drugs work by preventing the formation of blood clots, or by dissolving existing clots. Commonly used thrombosis drugs include anticoagulants, antiplatelet agents, and thrombolytics. Anticoagulants, such as warfarin and heparin, are used to prevent the formation of blood clots. Antiplatelet agents, such as aspirin and clopidogrel, are used to prevent the formation of clots in the arteries. Thrombolytics, such as alteplase and streptokinase, are used to dissolve existing clots.
Some companies in the Thrombosis Drug market include Bayer, Pfizer, Sanofi, Bristol-Myers Squibb, and Merck. Show Less Read more